The Effect of L-Arginine on the Clinical and Immunological Parameters in Patients with Asthma

Sayyora A. Bazarova, Anis L. Alyavi PhD, ScD, Gulnara S. Dzhambekova PhD, Gulnaz M. Kasymova PhD

Republican Specialized Scientific-Practical Medical Center of Therapy and Medical Rehabilitation, Tashkent, Uzbekistan.

*Corresponding author: Sayyora A. Bazarova, Republican Specialized Scientific-Practical Medical Center of Therapy and Medical Rehabilitation. 4, Osiyo street, Yunusabad district, 100084, Tashkent, Republic of Uzbekistan. Tel: 99894 6531358. E-mail:

Published: March 25, 2013


The purpose of this study was to study the effects of L-arginine on the clinical course and some immunological parameters in patients with asthma.

Material and Methods: In this study, we examined 56 patients with moderate and severe persistent asthma. The average duration of the disease was 15±2.3 years. The patients were divided into two groups. The patients of the study group (n=25) were subjected to the standard treatment and nitric oxide (NO) donor L-arginine. The patients of the comparison group (n=31) received the standard treatment only. All patients underwent a complete physical examination including a determination of serum cytokine levels (IL-4, IL-8, and TNF-α) before and after treatment.

Results: In both groups, the baseline serum levels of IL-4, IL-8 and TNF-α were greater than the normative values. Direct correlations were observed between the level of the interleukins and clinical symptoms. Daily intravenous infusion of L-arginine at 4.2 g for 30 min over 10 days significantly reduced the serum levels of IL-4, IL-8 and TNF-α. No significant changes were noted in the levels of these parameters in the control group.

Conclusion: The addition of L-arginine to the basic treatment in asthmatic patients contributed to the earlier improvement of clinical symptoms and a significant reduction of the IL-4, IL-8 and TNF-α serum levels.

asthma; L-arginine; interleukins; endothelial dysfunction.
  1. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Available from:
  2. Chuchalin AG.  Bronchial asthma.  M. : “Rus. Vrach” , 2001.   [ in Russian].
  3. Tattersfield AE , Knox AJ, Dritton JR, Hall IP. Asthma. Lancet 2003; 360(9342):1313-22.
  4. Barnes PJ. Cytokine modulators as novel therapies for asthma. Ann Rev Pharmacol Toxicol 2002; 42:81-98.
  5. Benson RC, Hardy KA, Morris CR. Arginase and arginine dysregulation in asthma. J Allergy (Cairo) 2011:736319. Epub 2011 Apr 26.
  6. Redington AE. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. European Journal of Pharmacology 2006; 533 (1–3): 263–276.
  7. Wanner A, Mendes ES. Airway endothelial dysfunction in asthma and chronic obstructive pulmonary disease: a challenge for future research. Am J Respir Crit Care Med 2010; Dec 1; 182(11):1344-51.
  8. Gozhenko AI, Kotyuzhinskaya SH, Kotyuzhinskiy AI. The role of nitric oxide in the regulation of microcirculation and blood aggregation. Ukrainian Medical Almanac 2000; 1:13-17. [in Russian].

The fully formatted PDF version is available.

Download Article

Int J Biomed. 2013; 3(1):12-14. © 2013 International Medical Research and Development Corporation. All rights reserved.